• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Weight homeostasis in hyperthyroidism and treatment with carbimazole

    Pravin Kumar Jha, Rajesh Kumar Jha

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 664-671

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background & objectives: Hyperthyroidism is related to expanded food consumption,
energy use and modified body synthesis. This study was meant to assess the job of
adipocytokines in weight homeostasis in patients with hyperthyroidism.
Methods: Patients (n=27, 11men) with hyperthyroidism (20 Graves' sickness, 7 harmful
multinodular goitres) with a mean period of 31.3±4.2 years and 28 sound Body Mass
Index (BMI) matched controls were examined. They went through an evaluation of
Lean Body Mass (LBM) and total muscle to total body fat (TBF) by double energy Xray
absorptiometer (DXA) and a blood test was taken in the fasting state for estimation
of leptin, adiponectin, ghrelin, insulin, glucose and lipids. Patients were reexamined
following 3 months of treatment as at that point every one of them accomplished
euthyroid state with carbimazole treatment.
Results: The LBM was higher (P<0.001) in sound controls when contrasted with
hyperthyroid patients even after a change for body weight (BW), though the absolute
muscle to fat ratio was similar between the two groups. Serum leptin levels were higher
in patients with hyperthyroidism than controls (22.3±3.7 and 4.1±0.34 ng/ml, P<0.001),
though adiponectin levels were tantamount. Plasma acylated ghrelin was higher in
patients than in controls (209.8±13.3 versus 106.2±8.2 pg/ml, P<0.05). The
accomplishment of euthyroidism was related to huge weight gain (P<0.001) and a huge
expansion in slender weight (P<0.001). The total muscle versus fat additionally
expanded however unimportantly from 18.4±1.8 to 19.9±1.8 kg. There was critical
lessening (P<0.05) in serum leptin and acylated ghrelin yet adiponectin levels stayed
unaltered after treatment. Serum leptin is decidedly associated with TBF and this
connection persevered even after changes for BW, BMI, orientation and age (r=0.62,
P=0.001). Nonetheless, serum leptin and acylated ghrelin didn't associate with the
presence or nonattendance of hyperphagia.
Conclusion: Patients with hyperthyroidism transcendently had diminished slender
weight which expanded after the accomplishment of euthyroidism with carbimazole.
The hyperphagia and the modifications in weight homeostasis related to
hyperthyroidism were autonomous of flowing leptin and ghrelin levels.
Keywords:
    Adipocytokines body composition ghrelin hyperphagia hyp
  • PDF (337 K)
  • XML
(2022). Weight homeostasis in hyperthyroidism and treatment with carbimazole. European Journal of Molecular & Clinical Medicine, 9(3), 664-671.
Pravin Kumar Jha, Rajesh Kumar Jha. "Weight homeostasis in hyperthyroidism and treatment with carbimazole". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 664-671.
(2022). 'Weight homeostasis in hyperthyroidism and treatment with carbimazole', European Journal of Molecular & Clinical Medicine, 9(3), pp. 664-671.
Weight homeostasis in hyperthyroidism and treatment with carbimazole. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 664-671.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 102
  • PDF Download: 146
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus